cilostazol has been researched along with Alloxan Diabetes in 36 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, the effects of the phosphodiesterase (PDE) inhibitors vardenafil and cilostazol were examined against rheumatoid arthritis (RA)/diabetes mellitus (DM)-co-morbidity-induced endothelial dysfunction and vascular reactivity defects." | 7.91 | Vardenafil and cilostazol can improve vascular reactivity in rats with diabetes mellitus and rheumatoid arthritis co-morbidity. ( Abo-Saif, AA; El-Daly, ME; Messiha, BAS; Wahba, MGF, 2019) |
| "Cilostazol is effective for the treatment of peripheral ischemia." | 7.79 | Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARγ. ( Angelini, F; Arena, V; Biscetti, F; Ferraccioli, G; Flex, A; Ghirlanda, G; Pecorini, G; Stigliano, E, 2013) |
| "To explore the effect of cilostazol in the pathophysiology of diabetic retinopathy and its mechanism, we intraperitoneal injection streptozotocin (STZ) to induce rats diabetic model to study the alteration of the thrombospondin-1 (TSP-1) in the retina of diabetic rats, cilostazol treatment diabetic rats and normal rats by immunohistochemistry, real-time quantitative reverse transcription-polymerase chain reaction." | 7.74 | The effect of cilostazol on expression of thrombospondin-1 in diabetic retinopathy. ( Gu, YS; Teng, XD; Wang, JY; Yan, LP; Zhang, XM, 2008) |
| "Treatment with cilostazol significantly reduced the ROS levels in the AqH compared to the diabetic rats." | 5.51 | Cilostazol Attenuates Retinal Oxidative Stress and Inflammation in a Streptozotocin-Induced Diabetic Animal Model. ( Chang, SW; Huang, YH; Lin, CW; Wang, LC; Yang, CH; Yang, CM; Yang, WS; Yeh, PT, 2019) |
| " Here, the effects of the phosphodiesterase (PDE) inhibitors vardenafil and cilostazol were examined against rheumatoid arthritis (RA)/diabetes mellitus (DM)-co-morbidity-induced endothelial dysfunction and vascular reactivity defects." | 3.91 | Vardenafil and cilostazol can improve vascular reactivity in rats with diabetes mellitus and rheumatoid arthritis co-morbidity. ( Abo-Saif, AA; El-Daly, ME; Messiha, BAS; Wahba, MGF, 2019) |
| "Cilostazol is effective for the treatment of peripheral ischemia." | 3.79 | Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARγ. ( Angelini, F; Arena, V; Biscetti, F; Ferraccioli, G; Flex, A; Ghirlanda, G; Pecorini, G; Stigliano, E, 2013) |
| " Recent studies have shown that cilostazol, a selective type 3 phosphodiesterase inhibitor, prevents neointimal hyperplasia and in-stent thrombosis in patients with diabetes after coronary angioplasty and stent implantation." | 3.75 | Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury. ( Cho, WH; Choi, HS; Hur, SH; Jung, GS; Kim, BW; Kim, HS; Kim, HT; Kim, JG; Kim, MK; Lee, HJ; Lee, IK; Lee, KM; Lee, KU; Lim, JO; Park, KG, 2009) |
| "To explore the effect of cilostazol in the pathophysiology of diabetic retinopathy and its mechanism, we intraperitoneal injection streptozotocin (STZ) to induce rats diabetic model to study the alteration of the thrombospondin-1 (TSP-1) in the retina of diabetic rats, cilostazol treatment diabetic rats and normal rats by immunohistochemistry, real-time quantitative reverse transcription-polymerase chain reaction." | 3.74 | The effect of cilostazol on expression of thrombospondin-1 in diabetic retinopathy. ( Gu, YS; Teng, XD; Wang, JY; Yan, LP; Zhang, XM, 2008) |
| "Treatment with cilostazol significantly reduced the ROS levels in the AqH compared to the diabetic rats." | 1.51 | Cilostazol Attenuates Retinal Oxidative Stress and Inflammation in a Streptozotocin-Induced Diabetic Animal Model. ( Chang, SW; Huang, YH; Lin, CW; Wang, LC; Yang, CH; Yang, CM; Yang, WS; Yeh, PT, 2019) |
| "Cilostazol was administered to rats intraperitoneally at dose 3 mg/kg." | 1.51 | The effect of cilostazol on hippocampal memory and oxidative stress biomarkers in rat model of diabetes mellitus. ( Ababneh, MA; Alzoubi, KH; Athamneh, RY; Mardini, AN; Rababa'h, AM, 2019) |
| "Cilostazol treatment significantly restored endothelial function in EPCs and HUVECs through activation of AMPK/acetyl-coenzyme A carboxylase (ACC)-dependent pathways and cAMP/protein kinase A (PKA)-dependent pathways." | 1.43 | Cilostazol improves high glucose-induced impaired angiogenesis in human endothelial progenitor cells and vascular endothelial cells as well as enhances vasculoangiogenesis in hyperglycemic mice mediated by the adenosine monophosphate-activated protein kin ( Chao, TH; Chen, JH; Cho, CL; Lee, CH; Li, YH; Liu, PY; Tseng, SY; Wu, HL, 2016) |
| "Cilostazol has potential for protecting vessels against hyperglycemic injury and for accelerating the healing process after implantation of DES." | 1.39 | Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model. ( Ahn, Y; Cho, HH; Hong, MH; Jeong, HY; Jeong, MH; Kang, WS; Kee, HJ; Kim, YS; Kwon, JS, 2013) |
| "Treatment with curcumin in control rats increased the sensitivity to cilostazol." | 1.38 | Curcumin increases vasodilatory effect of cilostazol in diabetic rat aorta. ( Belviranli, M; Gökbel, H; Nurullahoğlu-Atalik, KE; Okudan, N; Simşek, L, 2012) |
| "Cilostazol was administered (27 or 9 mg kg(-1)d(-1)) to streptozotocin (STZ)-induced diabetic rats for eight weeks." | 1.35 | Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats. ( Cao, M; Cheng, L; Gao, L; Guo, R; Hu, J; Li, M; Wang, F; Zhang, T; Zhang, X; Zhao, J, 2008) |
| "Cilostazol was administered orally at doses of 30 or 100 mg/kg twice a day for 1-2 weeks to rats." | 1.31 | Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. ( Kimura, Y; Marukawa, K; Sudo, T; Tani, T; Uehara, K; Yasuda, Y, 2000) |
| "Cilostazol or vehicle was administered to non-diabetic and streptozotocin-induced diabetic rats from 7 days before to 14 days after balloon injury of the carotid artery." | 1.31 | Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. ( Aoki, M; Hayashi, S; Jo, N; Kaneda, Y; Matsumoto, K; Morishita, R; Nakamura, T; Ogihara, T, 2001) |
| "Cilostazol treatment not only restored myelinated fiber density and size distribution but reversed some of the vascular abnormalities." | 1.30 | Effect of cilostazol on the neuropathies of streptozotocin-induced diabetic rats. ( Choi, YK; Kim, JW; Kim, SW; Kim, YS; Oh, SJ; Park, IK; Suh, KS; Woo, JT; Yang, IM, 1999) |
| "Cilostazol treatment (30 mg/kg/day p." | 1.29 | Effects of cilostazol on development of experimental diabetic neuropathy: functional and structural studies, and Na+ -K+ -ATPase acidity in peripheral nerve in rats with streptozotocin-induced diabetes. ( Furuta, M; Kishi, Y; Mukoyama, M; Naka, K; Nanjo, K; Sanke, T; Sasaki, H, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (22.22) | 18.2507 |
| 2000's | 13 (36.11) | 29.6817 |
| 2010's | 14 (38.89) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Tseng, SY | 3 |
| Chang, HY | 2 |
| Li, YH | 3 |
| Chao, TH | 3 |
| Nagai, N | 1 |
| Deguchi, S | 1 |
| Otake, H | 1 |
| Hiramatsu, N | 1 |
| Yamamoto, N | 1 |
| Wang, Z | 1 |
| Liu, T | 1 |
| Chen, X | 1 |
| You, H | 1 |
| Zhang, Q | 1 |
| Xue, J | 1 |
| Zheng, Y | 1 |
| Luo, D | 1 |
| Mohamed, MZ | 1 |
| Hafez, HM | 1 |
| Zenhom, NM | 1 |
| Mohammed, HH | 1 |
| Yeh, PT | 1 |
| Huang, YH | 1 |
| Chang, SW | 1 |
| Wang, LC | 1 |
| Yang, CM | 1 |
| Yang, WS | 1 |
| Lin, CW | 1 |
| Yang, CH | 1 |
| Rababa'h, AM | 1 |
| Mardini, AN | 1 |
| Alzoubi, KH | 1 |
| Ababneh, MA | 1 |
| Athamneh, RY | 1 |
| Wahba, MGF | 1 |
| Messiha, BAS | 1 |
| El-Daly, ME | 1 |
| Abo-Saif, AA | 1 |
| Wada, T | 1 |
| Onogi, Y | 1 |
| Kimura, Y | 3 |
| Nakano, T | 1 |
| Fusanobori, H | 1 |
| Ishii, Y | 1 |
| Sasahara, M | 1 |
| Tsuneki, H | 1 |
| Sasaoka, T | 1 |
| Kwon, JS | 1 |
| Kim, YS | 2 |
| Cho, HH | 1 |
| Kee, HJ | 1 |
| Hong, MH | 1 |
| Kang, WS | 1 |
| Jeong, HY | 1 |
| Jeong, MH | 1 |
| Ahn, Y | 1 |
| Biscetti, F | 1 |
| Pecorini, G | 1 |
| Arena, V | 1 |
| Stigliano, E | 1 |
| Angelini, F | 1 |
| Ghirlanda, G | 1 |
| Ferraccioli, G | 1 |
| Flex, A | 1 |
| Liu, PY | 1 |
| Lee, CH | 1 |
| Cho, CL | 1 |
| Wu, HL | 1 |
| Chen, JH | 1 |
| Kumar, A | 2 |
| Jaggi, AS | 1 |
| Singh, N | 1 |
| Tsukamoto, Y | 1 |
| Nagata, E | 1 |
| Fukuyama, N | 1 |
| Itoh, Y | 1 |
| Yuzawa, H | 1 |
| Kohara, S | 1 |
| Shimizu, M | 1 |
| Takahari, Y | 1 |
| Takizawa, S | 1 |
| Ota, H | 1 |
| Eto, M | 1 |
| Kano, MR | 1 |
| Ogawa, S | 1 |
| Iijima, K | 1 |
| Akishita, M | 1 |
| Ouchi, Y | 1 |
| Wang, F | 3 |
| Gao, L | 3 |
| Gong, B | 2 |
| Hu, J | 2 |
| Li, M | 2 |
| Guan, Q | 1 |
| Zhao, J | 3 |
| Matsumoto, T | 2 |
| Noguchi, E | 1 |
| Ishida, K | 1 |
| Nakayama, N | 1 |
| Kobayashi, T | 2 |
| Kamata, K | 2 |
| Wang, JY | 1 |
| Gu, YS | 1 |
| Yan, LP | 1 |
| Teng, XD | 1 |
| Zhang, XM | 1 |
| Cheng, L | 1 |
| Zhang, T | 1 |
| Cao, M | 1 |
| Guo, R | 1 |
| Zhang, X | 2 |
| Park, SY | 1 |
| Shin, HK | 1 |
| Lee, JH | 1 |
| Kim, CD | 1 |
| Lee, WS | 1 |
| Rhim, BY | 1 |
| Hong, KW | 1 |
| Lee, KM | 1 |
| Lee, HJ | 1 |
| Kim, MK | 1 |
| Kim, HS | 1 |
| Jung, GS | 1 |
| Hur, SH | 1 |
| Kim, HT | 1 |
| Cho, WH | 1 |
| Kim, JG | 1 |
| Kim, BW | 1 |
| Lim, JO | 1 |
| Choi, HS | 1 |
| Lee, KU | 1 |
| Park, KG | 1 |
| Lee, IK | 1 |
| Nurullahoğlu-Atalik, KE | 1 |
| Okudan, N | 1 |
| Belviranli, M | 1 |
| Gökbel, H | 1 |
| Simşek, L | 1 |
| Yamada, K | 1 |
| Niki, H | 1 |
| Nagai, H | 1 |
| Nishikawa, M | 1 |
| Nakagawa, H | 1 |
| Wakabayashi, K | 1 |
| Wang, B | 1 |
| Zhang, J | 1 |
| Suzuki, K | 1 |
| Uchida, K | 1 |
| Nakanishi, N | 1 |
| Hattori, Y | 1 |
| Kihara, M | 1 |
| Schmelzer, JD | 1 |
| Low, PA | 1 |
| Shindo, H | 1 |
| Tawata, M | 1 |
| Onaya, T | 1 |
| Naka, K | 2 |
| Sasaki, H | 3 |
| Kishi, Y | 2 |
| Furuta, M | 2 |
| Sanke, T | 2 |
| Nanjo, K | 2 |
| Mukoyama, M | 2 |
| Hotta, N | 2 |
| Koh, N | 2 |
| Sakakibara, F | 2 |
| Nakamura, J | 2 |
| Hamada, Y | 2 |
| Hara, T | 2 |
| Mori, K | 2 |
| Naruse, K | 1 |
| Fukasawa, H | 1 |
| Kakuta, H | 1 |
| Sakamoto, N | 1 |
| Nakashima, E | 1 |
| Kasama, N | 1 |
| Inukai, S | 1 |
| Yamamoto, Y | 2 |
| Yasuda, Y | 3 |
| Komiya, Y | 2 |
| Suh, KS | 1 |
| Oh, SJ | 1 |
| Woo, JT | 1 |
| Kim, SW | 1 |
| Yang, IM | 1 |
| Kim, JW | 1 |
| Choi, YK | 1 |
| Park, IK | 1 |
| Tani, T | 1 |
| Uehara, K | 1 |
| Sudo, T | 1 |
| Marukawa, K | 1 |
| Aoki, M | 1 |
| Morishita, R | 1 |
| Hayashi, S | 1 |
| Jo, N | 1 |
| Matsumoto, K | 1 |
| Nakamura, T | 1 |
| Kaneda, Y | 1 |
| Ogihara, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Effect of Cilostazol on the Clinical Outcomes of Rheumatoid Arthritis Patients[NCT05671497] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
36 other studies available for cilostazol and Alloxan Diabetes
| Article | Year |
|---|---|
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway.
Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me | 2022 |
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway.
Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me | 2022 |
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway.
Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me | 2022 |
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway.
Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me | 2022 |
Therapeutic Effect of Cilostazol Ophthalmic Nanodispersions on Retinal Dysfunction in Streptozotocin-Induced Diabetic Rats.
Topics: Animals; Cell Line; Cell Survival; Cilostazol; Diabetes Mellitus, Experimental; Diabetic Retinopathy | 2017 |
Low molecular weight fucoidan ameliorates hindlimb ischemic injury in type 2 diabetic rats.
Topics: Animals; Cilostazol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relat | 2018 |
Cilostazol alleviates streptozotocin-induced testicular injury in rats via PI3K/Akt pathway.
Topics: Animals; Cilostazol; Diabetes Complications; Diabetes Mellitus, Experimental; Glutathione; Heme Oxyg | 2018 |
Cilostazol Attenuates Retinal Oxidative Stress and Inflammation in a Streptozotocin-Induced Diabetic Animal Model.
Topics: Animals; Aqueous Humor; Blood Glucose; Blotting, Western; Chemokine CCL2; Chemokine CX3CL1; Cilostaz | 2019 |
The effect of cilostazol on hippocampal memory and oxidative stress biomarkers in rat model of diabetes mellitus.
Topics: Animals; Brain-Derived Neurotrophic Factor; Catalase; Cilostazol; Diabetes Mellitus, Experimental; G | 2019 |
Vardenafil and cilostazol can improve vascular reactivity in rats with diabetes mellitus and rheumatoid arthritis co-morbidity.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cardiovascular Diseases; Cilostazol; Comorb | 2019 |
Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Chronic Disease; Cilostazol; Diabetes Mellitus, E | 2013 |
Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model.
Topics: Administration, Oral; Angioplasty, Balloon; Animals; Aorta; Aortic Diseases; Apoptosis; Blood Glucos | 2013 |
Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARγ.
Topics: Angiogenesis Inducing Agents; Animals; Cilostazol; Diabetes Mellitus, Experimental; Hindlimb; Ischem | 2013 |
Cilostazol improves high glucose-induced impaired angiogenesis in human endothelial progenitor cells and vascular endothelial cells as well as enhances vasculoangiogenesis in hyperglycemic mice mediated by the adenosine monophosphate-activated protein kin
Topics: AMP-Activated Protein Kinases; Angiogenesis Inducing Agents; Animals; Cell Adhesion; Cell Movement; | 2016 |
Efficacy of Cilostazol a selective phosphodiesterase-3 inhibitor in rat model of Streptozotocin diabetes induced vascular dementia.
Topics: Animals; Blood Glucose; Body Weight; Brain Chemistry; Cilostazol; Dementia, Vascular; Diabetes Melli | 2015 |
Cilostazol protects against microvascular brain injury in a rat model of type 2 diabetes.
Topics: Animals; Brain Injuries; Cilostazol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dis | 2017 |
Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells.
Topics: Acetylation; Animals; Benzamides; Cell Shape; Cells, Cultured; Cellular Senescence; Cilostazol; Cycl | 2008 |
Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol.
Topics: Animals; Aorta, Thoracic; Cilostazol; Cyclic AMP; Diabetes Mellitus, Experimental; Hypoglycemic Agen | 2008 |
Cilostazol improves endothelial dysfunction by increasing endothelium-derived hyperpolarizing factor response in mesenteric arteries from Type 2 diabetic rats.
Topics: Acetylcholine; Animals; Biological Factors; Cilostazol; Cyclic AMP; Diabetes Mellitus, Experimental; | 2008 |
The effect of cilostazol on expression of thrombospondin-1 in diabetic retinopathy.
Topics: Animals; Cilostazol; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Immunohistochemistry; In | 2008 |
Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemokine CCL2; Cilostazol; Diabetes Mellitus, Exp | 2008 |
Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.
Topics: 3T3-L1 Cells; Adiponectin; Adipose Tissue; Animals; Biomarkers; Blood Glucose; Body Weight; Cilostaz | 2009 |
Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury.
Topics: Angioplasty, Balloon; Angiotensin II; Animals; Binding Sites; Blood Glucose; Carotid Arteries; Carot | 2009 |
Curcumin increases vasodilatory effect of cilostazol in diabetic rat aorta.
Topics: Animals; Aorta, Thoracic; Blood Glucose; Body Weight; Cilostazol; Curcumin; Diabetes Mellitus, Exper | 2012 |
Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT(2A) receptors in promoting thrombosis in diabetes.
Topics: Animals; Aspirin; Cells, Cultured; Cilostazol; Diabetes Mellitus, Experimental; Fibrinolytic Agents; | 2012 |
Cilostazol improves endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats.
Topics: Animals; Biological Factors; Blood Glucose; Blotting, Western; Calcimycin; Cholesterol; Cilostazol; | 2005 |
Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-kappa B-dependent down-regulation of vascular cell adhesion molecule-1 expression.
Topics: Animals; Cilostazol; Diabetes Mellitus, Experimental; Down-Regulation; Endothelium, Vascular; Gene E | 2006 |
Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes.
Topics: AMP-Activated Protein Kinases; Animals; Aorta; Blood Glucose; Blotting, Western; Cells, Cultured; Ch | 2008 |
Effect of cilostazol on experimental diabetic neuropathy in the rat.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Cilostazol; Diabetes Mellitus, Experimental; Di | 1995 |
Cyclic adenosine 3',5'-monophosphate enhances sodium, potassium-adenosine triphosphatase activity in the sciatic nerve of streptozotocin-induced diabetic rats.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Bucladesine; Cilostazol; Cyclic AMP; Diabetes Mellitus, Experi | 1993 |
Effects of cilostazol on development of experimental diabetic neuropathy: functional and structural studies, and Na+ -K+ -ATPase acidity in peripheral nerve in rats with streptozotocin-induced diabetes.
Topics: Animals; Blood Glucose; Body Weight; Cilostazol; Cyclic AMP; Diabetes Mellitus, Experimental; Diabet | 1995 |
Nerve function and blood flow in Otsuka Long-Evans Tokushima Fatty rats with sucrose feeding: effect of an anticoagulant.
Topics: 2,3-Diphosphoglycerate; Alcohols; Animals; Anticoagulants; Blood Glucose; Body Weight; Carbohydrate | 1996 |
The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats.
Topics: Aldehyde Reductase; Animals; Atrophy; Cilostazol; Diabetes Mellitus, Experimental; Drug Synergism; E | 1997 |
Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant.
Topics: 2,3-Diphosphoglycerate; Aldehyde Reductase; Animals; Anticoagulants; Blood Glucose; Body Weight; Cil | 1997 |
Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats.
Topics: Animals; Axons; Blood Glucose; Body Weight; Cilostazol; Diabetes Mellitus, Experimental; Diabetic Ne | 1998 |
Effect of cilostazol on the neuropathies of streptozotocin-induced diabetic rats.
Topics: Animals; Cilostazol; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Male; Neura | 1999 |
Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats.
Topics: Animals; Anticoagulants; Blood Glucose; Cholesterol, HDL; Cilostazol; Diabetes Mellitus, Experimenta | 2000 |
Cilostazol prevents impairment of slow axonal transport in streptozotocin-diabetic rats.
Topics: Animals; Axonal Transport; Blood Glucose; Body Weight; Cilostazol; Cytoskeletal Proteins; Diabetes M | 2000 |
Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Acetylcholine; Animals; Aorta; Arteries; Carotid Arteries; C | 2001 |